SCHEMBL19944669

SCHEMBL19944669

CCOC(=O)C[C@H](CC(=O)OC(C)(C)C)NC(=O)OC(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
HTT P42858 1/20 0.52
CYP2D6 P10635 1/20 0.51
CTSK P43235 5/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
TP53 P04637 1/20 0.40
CTSS P25774 2/20 0.40
MGAM O43451 1/20 0.39
GAA P10253 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22866107 0.97 CYP1A2 (0.55) CYP1A2CYP2C9CYP2C19HTTCYP2D6
SCHEMBL3414965 0.89 CYP1A2 (0.51) CYP1A2CYP2C9CYP2C19HTTCYP2D6
SCHEMBL18343731 0.88 CYP1A2 (0.50) CYP1A2CYP2C9CYP2C19HTTCYP2D6
SCHEMBL7834317 0.85 CYP2D6 (0.55) CYP1A2CYP2C9CYP2C19HTTCYP2D6
SCHEMBL18428106 0.85 CYP2D6 (0.55) CYP1A2CYP2C9CYP2C19HTTCYP2D6
SCHEMBL24387320 0.84 CYP1A2 (0.47) CYP1A2CYP2C9CYP2C19HTTCYP2D6
SCHEMBL31251106 0.84 CYP1A2 (0.47) CYP1A2CYP2C9CYP2C19HTTCYP2D6
SCHEMBL18427981 0.83 CYP2D6 (0.54) CYP1A2CYP2C9CYP2C19HTTCYP2D6
SCHEMBL17603553 0.83 CYP2D6 (0.54) CYP1A2CYP2C9CYP2C19HTTCYP2D6
SCHEMBL1747220 0.82 CYP1A2 (0.54) CYP1A2CYP2C9CYP2C19HTTCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10975119-B2 Selective cysteine protease inhibitors and uses thereof GENESIS TECHNOLOGIES LIMITED (BB) 2021-04-13 US disclosed
US-20180186833-A1 SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF GENESIS TECH LIMITED (BB) 2018-07-05 US disclosed
US-9944674-B2 Selective cysteine protease inhibitors and uses thereof GENESIS TECHNOLOGIES LIMITED (BB) 2018-04-17 US disclosed
EP-2697246-B1 SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF GENESIS TECH LIMITED (BB) 2018-03-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180186833-A1 SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF SERPINB1, SERPINE1, CASP5 CYP1A2 2156/4885CYP2C9 1709/4885CYP2C19 2513/4885
US-10975119-B2 Selective cysteine protease inhibitors and uses thereof SERPINB1, SERPINE1, CASP5 CYP1A2 2138/4885CYP2C9 1705/4885CYP2C19 2577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.